SE0401790D0 - Tamoxifen response in pre- and postmenopausal breast cancer patients - Google Patents

Tamoxifen response in pre- and postmenopausal breast cancer patients

Info

Publication number
SE0401790D0
SE0401790D0 SE0401790A SE0401790A SE0401790D0 SE 0401790 D0 SE0401790 D0 SE 0401790D0 SE 0401790 A SE0401790 A SE 0401790A SE 0401790 A SE0401790 A SE 0401790A SE 0401790 D0 SE0401790 D0 SE 0401790D0
Authority
SE
Sweden
Prior art keywords
breast cancer
cancer patients
postmenopausal breast
tamoxifen response
tamoxifen
Prior art date
Application number
SE0401790A
Other languages
English (en)
Inventor
Goeran Landberg
Lisa Ryden
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Priority to SE0401790A priority Critical patent/SE0401790D0/sv
Publication of SE0401790D0 publication Critical patent/SE0401790D0/sv
Priority to PCT/SE2005/001116 priority patent/WO2006004545A1/en
Priority to EP05757471A priority patent/EP1773309A1/en
Priority to US11/620,275 priority patent/US20070213403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0401790A 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients SE0401790D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients
PCT/SE2005/001116 WO2006004545A1 (en) 2004-07-07 2005-07-06 Tamoxifen response in pre-and postmenopausal breast cancer patients
EP05757471A EP1773309A1 (en) 2004-07-07 2005-07-06 Tamoxifen response in pre-and postmenopausal breast cancer patients
US11/620,275 US20070213403A1 (en) 2004-07-07 2007-01-05 Tamoxifen response in pre-and postmenopausal breast cancer patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients

Publications (1)

Publication Number Publication Date
SE0401790D0 true SE0401790D0 (sv) 2004-07-07

Family

ID=32768801

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients

Country Status (4)

Country Link
US (1) US20070213403A1 (sv)
EP (1) EP1773309A1 (sv)
SE (1) SE0401790D0 (sv)
WO (1) WO2006004545A1 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2007004765A (es) 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
CA2869313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Gene expression panel for breast cancer prognosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539588A (en) * 1967-12-06 1970-11-10 American Home Prod Trans-1,4,4a,5,6,11b-hexahydro-11h-benzo(a) carbazol-5-one,thiosemicarbazones
US4769378A (en) * 1986-03-31 1988-09-06 Eli Lilly And Company Indenopyrimidine aromatase inhibitors
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
WO2000034788A1 (en) * 1998-12-08 2000-06-15 Board Of Regents, The University Of Texas System Methods for detection of antiestrogen-resistant breast cancer
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
CN1329390C (zh) * 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
AU2001296578A1 (en) * 2000-10-06 2002-04-22 Biomedicines, Inc Combination therapy for the treatment of estrogen-sensitive disease
US6686362B2 (en) * 2001-12-27 2004-02-03 Theravance, Inc. Indolinone derivatives
WO2003068229A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
WO2006004545A1 (en) 2006-01-12
EP1773309A1 (en) 2007-04-18
US20070213403A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
CY1111729T1 (el) Υπογλωσσιο επικαλυμμενο δισκιο
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
AP2002002561A0 (en) 5-HT receptor ligards and uses thereof.
TNSN07005A1 (fr) Analogues tetrapeptidiques
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
CR10266A (es) Software y metodos para la planeación de tratamientos dentales
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
ATE486890T1 (de) Ephb-rezeptorbindende peptide
TN2009000371A1 (fr) Composition pharmaceutique
MX2008013827A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
DK1729753T3 (da) Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
ATE556071T1 (de) Kappa-opioidrezeptor-liganden
HUP0402281A2 (hu) Endotelin receptor antagonisták alkalmazása daganatos betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ATE548365T1 (de) 5-ht7-rezeptorantagonisten
LT2012006A (lt) 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui
DK2001456T3 (da) Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций